Does MOGAMULIZUMAB Cause Myelosuppression? 11 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Myelosuppression have been filed in association with MOGAMULIZUMAB (POTELIGEO). This represents 2.5% of all adverse event reports for MOGAMULIZUMAB.
11
Reports of Myelosuppression with MOGAMULIZUMAB
2.5%
of all MOGAMULIZUMAB reports
6
Deaths
10
Hospitalizations
How Dangerous Is Myelosuppression From MOGAMULIZUMAB?
Of the 11 reports, 6 (54.5%) resulted in death, 10 (90.9%) required hospitalization, and 4 (36.4%) were considered life-threatening.
Is Myelosuppression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for MOGAMULIZUMAB. However, 11 reports have been filed with the FAERS database.
What Other Side Effects Does MOGAMULIZUMAB Cause?
Rash (59)
Disease progression (46)
Infusion related reaction (42)
Pyrexia (35)
Febrile neutropenia (29)
Erythema (28)
Pruritus (26)
Drug ineffective (24)
Constipation (22)
Death (21)
What Other Drugs Cause Myelosuppression?
CYCLOPHOSPHAMIDE (3,603)
CARBOPLATIN (2,624)
TRASTUZUMAB (2,552)
PACLITAXEL (2,522)
TISLELIZUMAB (2,142)
CYTARABINE (1,869)
VENETOCLAX (1,864)
CISPLATIN (1,849)
BEVACIZUMAB (1,744)
SODIUM (1,696)
Which MOGAMULIZUMAB Alternatives Have Lower Myelosuppression Risk?
MOGAMULIZUMAB vs MOGAMULIZUMAB-KPKC
MOGAMULIZUMAB vs MOLNUPIRAVIR
MOGAMULIZUMAB vs MOLSIDOMINE
MOGAMULIZUMAB vs MOMELOTINIB
MOGAMULIZUMAB vs MOMETASONE